You are here: Industry Insights > Alnylam

News List

Regeneron and Alnylam partner on eye and CNS disease therapies pharmaceutical-technology
April 23, 2019
Regeneron and Alnylam partner on eye and CNS disease therapies.
Alnylam and Sanofi close research phase of 2014's $700m RNAi rare disease partnership pharmafile
April 11, 2019
Alnylam and Sanofi have announced their intention to bring to an end the research and option phase of a $700 million partnership originally launched in 2014 to develop RNAi therapeutics for rare conditions.
Regeneron, Alnylam Ink RNAi Alliance contractpharma
April 09, 2019
To discover, develop and commercialize new RNA interference therapeutics for a broad range of diseases
Sanofi and Alnylam Amend Rare Disease Alliance contractpharma
April 09, 2019
Sanofi and Alnylam Amend Rare Disease Alliance
Alnylam partners with Medison to offer Onpattro in Israel pharmaceutical-technology
January 23, 2019
US-based Alnylam Pharmaceuticals has signed an exclusive agreement with Medison Pharma to commercialise its RNAi therapeutic Onpattro in Israel....
NICE rejects Alnylam and Akcea’s amyloidosis drugs pharmaphorum
December 14, 2018
NICE has rejected two pioneering drugs for the rare inherited condition, hereditary transthyretin-related amyloidosis (hATTR) in first draft guidance.
U.K. cost watchdog NICE issues preliminary ‘no’ on Alnylam’s Onpattro and Ionis’ Tegsedi fiercepharma
December 14, 2018
Alnylam and Ionis are in a head-to-head battle for market share with their new treatments for the rare disease hereditary transthyretin-mediated amyloidosis (ATTR)...
Alnylam Announces Board of Directors Appointment americanpharmaceuticalreview
October 12, 2018
Alnylam Pharmaceuticals announced the appointment of Dr. Margaret Hamburg to its Board of Directors effective January 10, 2019.
Alnylam’s RNA therapy Onpattro bags EU nod pharmatimes
September 14, 2018
Alnylam’s RNAi therapeutic Onpattro has been approved for use in Europe to treat Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR amyloidosis)...
Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran americanpharmaceuticalreview
August 22, 2018
Alnylam has achieved full patient accrual in its ENVISION Phase 3 study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the treatment of acute hepatic porphyrias (AHPs).

Previous page 1 2 3 Next page